| 98 -0.66 (-0.67%) | 09-09 14:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 126.87 |
1-year : | 140.54 |
| Resists | First : | 108.62 |
Second : | 120.33 |
| Pivot price | 106.92 |
|||
| Supports | First : | 89.69 |
Second : | 74.63 |
| MAs | MA(5) : | 101.36 |
MA(20) : | 103.3 |
| MA(100) : | 95.4 |
MA(250) : | 98.69 |
|
| MACD | MACD : | 1.4 |
Signal : | 2.8 |
| %K %D | K(14,3) : | 24.3 |
D(3) : | 34.8 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 124 | Low : | 79.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BNTX ] has closed above bottom band by 12.0%. Bollinger Bands are 68.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 101.44 - 101.95 | 101.95 - 102.37 |
| Low: | 97.01 - 97.55 | 97.55 - 97.99 |
| Close: | 97.88 - 98.71 | 98.71 - 99.4 |
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Tue, 08 Sep 2026
BioNTech(BNTX.US) 10% Shareholder Sells US$7.89 Million in Common Stock - Moomoo
Tue, 08 Sep 2026
BioNTech (NASDAQ: BNTX) CEO sells shares in planned trades - Stock Titan
Tue, 08 Sep 2026
How Trial Termination At BioNTech (BNTX) Has Changed Its Investment Story - simplywall.st
Tue, 08 Sep 2026
BioNTech Shares Fall After BMO Downgrade and Price Target Cut - Yahoo Finance
Mon, 07 Sep 2026
BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy? - Yahoo Finance
Mon, 07 Sep 2026
BioNTech SE (BNTX) Stock Analysis: Navigating Growth Amidst A 15.99% Upside Potential - directorstalkinterviews.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 251 (M) |
| Shares Float | 108 (M) |
| Held by Insiders | 57.5 (%) |
| Held by Institutions | 20.3 (%) |
| Shares Short | 2,510 (K) |
| Shares Short P.Month | 2,270 (K) |
| EPS | -7.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 82.19 |
| Profit Margin | -63.7 % |
| Operating Margin | -806.7 % |
| Return on Assets (ttm) | -5.5 % |
| Return on Equity (ttm) | -9.4 % |
| Qtrly Rev. Growth | -59.5 % |
| Gross Profit (p.s.) | 8.08 |
| Sales Per Share | 10.54 |
| EBITDA (p.s.) | -5.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 680 (M) |
| Levered Free Cash Flow | -250 (M) |
| PE Ratio | -12.58 |
| PEG Ratio | 0 |
| Price to Book value | 1.18 |
| Price to Sales | 9.26 |
| Price to Cash Flow | 36.11 |
| Dividend | 2.1 |
| Forward Dividend | 0 |
| Dividend Yield | 2.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|